Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
MINDACT breast cancer clinical trial: First results and impact on future trial design

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 27.04.16
Views: 3821
Rating:

Dr Martine Piccart - Jules Bordet Institute, Brussels, Belgium

Dr Martine Piccart speaks with ecancertv at AACR 2016 about the results of the MINDACT trial.

Using a new diagnostic assay, Mammaprint, to scan for a 70 gene signature, Dr Piccart reports significant predictive potential for determining breast cancer relapse risk.

With breast cancer being knowingly over-treated, the results from this trial enable the reduction of unnecessary treatments, even in patients classified as high risk via Adjuvant!Online, and lead to strategic de-escalation of chemotherapy.

For more specific results from the trial, you can view Dr Piccart presenting to the conference here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation